Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 1997

View Archived Issues

Arris and Bayer modify collaboration

Ganciclovir implant effective in treating CMV retinitis

Future therapeutic targets for AD

Company Profile: Biorex

Merck Sharp & Dohme reveals new tachykinin antagonists

HIV protease inhibitors from Novartis

Acetylcholine receptor modulators reported by SIBIA Neurosciences

Biomedica Foscama discloses adenosine antagonists for depression

Potent, orally active fibrinogen antagonist developed at Merck & Co.

Novel antiinflammatory agents prepared by French investigators

FDA approves first medical device for epilepsy

Cell Pathways reports chemoprotective activity of sulindac sulfone in animal model

Preliminary results from IMpact-RSV trial

Low-dose interferon alfa nears phase III for the treatment of Sjogren's syndrome

Mycophenolic acid derivatives with immunosuppressive activity claimed

Final dosimetry analysis of phase II/III trial of Oncolym

Kanebo reports novel cell adhesion inhibitors

RiboGene and Trega Biosciences extend drug discovery collaboration

FK-143: promising new BPH therapy

Fibrinogen-antagonistic oxopiperazine derivatives from Yamanouchi

Nisshin Flour Milling describes new antiasthma drugs

New cardiovascular drugs reported by Yamanouchi

Preliminary results reported for lisofylline in acute myeloid leukemia phase II trial

RS-67506 enhances lower intestinal propulsion in mice

Possible mechanism of antiarthritic activity of TA-383 reported

SIGA and Wyeth-Ayerst commence discovery program for novel antiinfectives

Dose-response trial of LAAM in opioid-dependent subjects

Promising preliminary results reported for Interneuron's ischemic stroke treatment

Isis and Ciba Vision sign distribution agreement for novel CMV retinitis drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...